drugset / Trial / NCT06534060
MB-105 in Patients With CD5 Positive T-cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon two-stage optimal design.
Timeline
- Start
- 2025-02-15
- Primary completion
- 2028-02
- Completion
- 2029-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MB-105 | Cell therapy | 5e+07 cells | — |